12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Reparixin: Phase III started

Dompe began a double-blind, international Phase III trial to evaluate reparixin in about 60 patients. The compound has Orphan Drug designation in the...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >